Gliclazide Use in CKD Stage 4

Introduction to Gliclazide

Gliclazide is a preferred second-generation sulfonylurea that can be safely used in patients with CKD stage 4 (eGFR 15-29 ml/min/1.73m²) as it does not have active metabolites and does not significantly increase the risk of hypoglycemia compared to other sulfonylureas 1, 2

Gliclazide is metabolized primarily by the liver and does not rely on kidney elimination of active metabolites, making it safer than first-generation sulfonylureas in CKD 2, 3
Unlike first-generation sulfonylureas, gliclazide can be used with appropriate dose adjustments in CKD stage 4 patients 1, 3
Among second-generation sulfonylureas, gliclazide and glipizide are preferred agents in CKD as they do not have active metabolites that accumulate 2, 4

Start with a lower initial dose in CKD stage 4 patients and titrate cautiously 3, 4
Monitor blood glucose levels closely after initiation and with any dose adjustments to avoid hypoglycemia 3
Conservative dosing is recommended due to the increased risk of hypoglycemia in advanced CKD 5, 4

Patients with CKD stage 4 have increased risk of hypoglycemia due to decreased clearance of insulin and some oral antidiabetic agents 1, 3
Impaired renal gluconeogenesis due to reduced kidney mass also contributes to the increased risk of hypoglycemia in CKD stage 4 patients 2, 3
Monitor glucose levels more frequently in CKD stage 4 patients on gliclazide 3
Consider reducing doses of other antihyperglycemic medications when adding gliclazide to prevent hypoglycemia 6

If glycemic targets are not met with gliclazide or hypoglycemia is a concern, consider GLP-1 receptor agonists which have been studied with eGFR as low as 15 ml/min/1.73m² 7, 8
SGLT2 inhibitors can be initiated with eGFR 20-29 ml/min/1.73m² primarily for their kidney and cardiovascular benefits, though their glucose-lowering effect is minimal at this level of kidney function 6, 7
Repaglinide is another option for CKD stage 4 patients, starting at 0.5mg with meals and titrating cautiously 8

More frequent blood glucose monitoring is essential in CKD stage 4 patients on gliclazide 3, 4
HbA1c may be less reliable in advanced CKD due to reduced red blood cell lifespan, hemolysis, and other factors affecting its accuracy 1, 8
Consider less stringent glycemic targets (HbA1c ~7.0%) for patients with CKD stage 4 who are at risk of hypoglycemia and have clinically significant comorbidities 3, 9

Avoid using gliclazide in combination with gemfibrozil as it may increase the risk of hypoglycemia 1, 2
Use caution when combining with other medications that may increase hypoglycemia risk 4
In case of acute illness, surgery, or prolonged fasting, consider temporarily reducing or suspending gliclazide to prevent hypoglycemia 6